louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01347502: Prevalence of Bacterial Contamination on Smart Cell Phone vs. Non-smart Phone
Official title: Bacterial Contamination of Smart Phones of Health Care Workers
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Health Care Workers, Including Physicians, Nurses, and Nursing Aids
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2011-05-04
Enrollment: 203
Sex: ALL
Minimum age (years): 19
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: healthcare providers of MICU in Seoul national university hospital and Seoul national university Bundang hospital who have cellular phones

Brief summary: Using smartphone is increasing in hospital with various purpose and it has more extended surface than non-smart phone. Therefore investigators can consider the bacterial contamination rate of smartphone will be higher than that of non-smartphone.

Detailed description: Hospital-acquired infections(HAI) are causing grave concern in almost all the hospitals of the world and causing increased morbidity and mortalities.

The transmission of HAI occurs through hospital staff and inanimate hospital environment, equipment, and devices that the hospital staff use.Recently, cellphones (CP) were blamed to cause nosocomial infections.

The mobile phones are used routinely all day long but not cleaned properly, as health care workers' may do not wash their hands as often as they should. The aim of the present study was to evaluate the prevalence of bacterial contamination of mobile phones in ICU health care providers. and especially compare the contamination rate between smartphone and non-smartphone.

Using smartphone is increasing in hospital with various purpose and it has more extended surface than non-smart phone. therefore we can consider the bacterial contamination rate of smartphone will be higher than that of non-smartphone.

Eligibility criteria: Inclusion Criteria:

* healthcare providers of MICU who have cellular phones

Exclusion Criteria:

* healthcare providers of MICU who have not cellular phones

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Seongnam-si
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
state: Gyeonggi-do
city: Seoul
country: Korea, Republic of
facility: Seoul Metropolitan Government Seoul National University Boramae Medical Center
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
affiliation: Seoul National University Hospital
name: Jae-Joon Yim, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Lee YJ, Yoo CG, Lee CT, Chung HS, Kim YW, Han SK, Yim JJ. Contamination rates between smart cell phones and non-smart cell phones of healthcare workers. J Hosp Med. 2013 Mar;8(3):144-7. doi: 10.1002/jhm.2011. Epub 2013 Feb 15.
Clinical trial NCT03427502: Anterior Ethmoidal Nerve Block in Prevention of Postoperative Agitation
Official title: Anterior Ethmoidal Nerve Block in Prevention of Postoperative Agitation Following Nasal Surgeries With Nasal Packs Under General Anesthesia: A Double Blind Randomized Control Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Postoperative Agitation: Impaired Awareness, Abnormal Cognitive Function, Confusion, and Verbal and Physical Agitation During Recovery From General Anesthesia
Deviated Nasal Septum
Chronic Rhinosinusitis (Diagnosis)
Nasal Polyps
Keywords: general anesthesia
nasal surgery
anterior ehtmoidal nerve block
bupivacaine
postoperative confusion
Lead sponsor: Lumbini Medical College
Sponsor class: OTHER
First posted: 2018-02-09
Enrollment: 100
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Postoperative agitation is an important complication of general anesthesia, moreover, it has been found with high incidence in ear, nose, throat (ENT) surgeries. We aim to study whether anterior ethmoidal nerve block will be successful in reducing postoperative agitation in those patients. Study population will be randomized into two groups, treatment and control group. Anterior ethmoidal nerve block will be done in treatment group and postoperative agitation compared between these two groups. Agitation score will be scored with Riker Sedation-Agitation Scale (SAS).

Ho: Occurrence of post-operative agitation in patients undergoing nasal surgery with nasal pack under general anesthesia is equal in those with ethmoidal nerve block as compared to those without the block.

Ha: Occurrence of post-operative agitation in patients undergoing nasal surgery with nasal pack under general anesthesia is not equal in those with ethmoidal nerve block as compared to those without the block.


Eligibility criteria: Inclusion Criteria:

* Patients undergoing nasal surgery
* Under General Anesthesia
* With nasal packs

Exclusion Criteria:

* Do not consent to the study.
* History of allergy to lignocaine or bupivacaine

Primary outcomes:
measure: Postoperative agitation
timeFrame: After extubation before leaving operation table, an average of 10 minutes
measure: Postoperative agitation
timeFrame: 30 minutes after first score.
measure: Postoperative agitation
timeFrame: 9:00 AM next morning
Secondary outcomes:
Other outcomes:
Locations:
city: Tansen
country: Nepal
facility: Lumbini Medical College
state: Palpa
Study officials:
References:
Clinical trial NCT03855202: The Treatment of Bronchopulmonary Dysplasia by Instillation PS and Mononuclaer Cells in Preterms
Official title: The Treatment of Bronchopulmonary Dysplasia by Instillation PS and Mononuclaer Cells in Preterms
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Neonates Premature
Ventilator Support
Keywords: PS
cord blood mononuclaer Cells
preterm
Lead sponsor: Guangdong Women and Children Hospital
Sponsor class: OTHER
First posted: 2019-02-26
Enrollment: 320
Sex: ALL
Minimum age (years): 28
Maximum age (years): 36
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Bronchopulmonary dysplasia mainly occurs in premature infants, which is the main cause of premature infant death.If children with BPD can survive, they are also prone to complications of long-term respiratory diseases such as asthma,that affect the quality of life of BPD children. However, there is no effective treatment method for BPD. So,the investigator would like to investigate the effect of Intratracheal PS and mononuclaer cells in pretems

Detailed description: This is a Phase 1 clinical trial that constitues one time points cohor and three group,each group with 80 participants,which receive intratracheal PS and mononuclaer cells,receive intratracheal PS,receive intratracheal mononuclaer cells.

1. Eligibility Criteria:Preterm(gestational age more than 28weeks and less than 37weeks)
2. Exlusion criteria: Preterm infants with major congenital malformations,chromosomal anomalies,inborn errors of metabolism and clinical or laboratory evidence of a congenital infection
3. Demographic Data and Baseline characteristics of the study groups were collected:

Gestational age(weeks) birth weight(g) gender Cesarean section delivery antenatal steroids prolonged rupture of membrane Multiple pregnancies APGAR score at 5 minutes Thrombocytopenia before intervention CRP befor intervention(mg/l) TNF-αbefore intervention（pg/ml） 4.Autologous cord blood mononuclear cells doses is 25million cells/kg 5.the following are monitored at 3、7、14、21 days after birth: mortality, incidence of bronchopulmonary dysplasia 5.Long-term follow up:in 1m，3m，6m,1y:neurodevelopment,asthma，anemia and physic growth

Eligibility criteria: Inclusion Criteria:

twenty-eight weeks to thirty-seven weeks

Exclusion Criteria:

Pretem infants with major congenital malformations,chromosomal anomalies,inborn errors of metabolism and clinical or laboratory evidence of a congenital infection

Primary outcomes:
measure: number of patients who died
timeFrame: up to 21 days after birth
Secondary outcomes:
measure: number of patients with neurodevelopmental disorder assessed by Bayley Score
timeFrame: up to 1 month, 3 month, 6 months and 1 year
Other outcomes:
Locations:
Study officials:
affiliation: Guangdong Women and Children Hospital
name: Jie Yang, PHD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01368302: Attention Bias Modification Treatment (ABMT) for Patients With Post Traumatic Stress Disorder (PTSD)
Official title: Attention Bias Modification Treatment (ABMT) for Patients With Post Traumatic Stress Disorder (PTSD)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Attention Bias Modification Treatment (ABMT)
Keywords: attention bias modification treatment
cognitive bias modification
attention training
anxiety
Lead sponsor: Tel Aviv University
Sponsor class: OTHER
First posted: 2011-06-07
Enrollment: 52
Sex: MALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: BASIC_SCIENCE

Brief summary: Patients with Post Traumatic Stress Disorder (PTSD) will be randomly assigned to either Attention Bias Modification Treatment (ABMT) designed to normalize threat-related attention biases or a placebo control condition not designed to change attention patterns. Outcome measures will be Post Traumatic Stress Disorder (PTSD), depression, and anxiety symptoms as measured by gold standard questionnaires and symptom counts derived from structured clinical interviews.

We expect to see significant Post Traumatic Stress Disorder symptom reduction in the Attention Bias Modification Treatment (ABMT) group relative to the placebo control group in which no symptomatic relief is expected.


Eligibility criteria: Inclusion Criteria:

* Combat-related PTSD diagnosis

Exclusion Criteria:

* Other treatment

Primary outcomes:
measure: Clinician-Administered PTSD Scale (CAPS)
timeFrame: 40 minutes
Secondary outcomes:
measure: PTSD Check List (PCL)
timeFrame: 10 minutes
Other outcomes:
Locations:
city: Tel Aviv
country: Israel
facility: Tel Aviv University
Study officials:
References:
citation: Hakamata Y, Lissek S, Bar-Haim Y, Britton JC, Fox NA, Leibenluft E, Ernst M, Pine DS. Attention bias modification treatment: a meta-analysis toward the establishment of novel treatment for anxiety. Biol Psychiatry. 2010 Dec 1;68(11):982-90. doi: 10.1016/j.biopsych.2010.07.021.
citation: Badura-Brack AS, Naim R, Ryan TJ, Levy O, Abend R, Khanna MM, McDermott TJ, Pine DS, Bar-Haim Y. Effect of Attention Training on Attention Bias Variability and PTSD Symptoms: Randomized Controlled Trials in Israeli and U.S. Combat Veterans. Am J Psychiatry. 2015 Dec;172(12):1233-41. doi: 10.1176/appi.ajp.2015.14121578. Epub 2015 Jul 24.
Clinical trial NCT01394302: The Functional Profile of People Suffering From Trigger Finger
Official title: Functional Profile of People Suffering From Trigger Finger
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Trigger Finger
Keywords: Trigger Finger
Lead sponsor: Meir Medical Center
Sponsor class: OTHER
First posted: 2011-07-14
Enrollment: 60
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients who come to visit The hand Specialist doctor and receive a diagnosis of TF.

Brief summary: The purpose of this study is to Characterize the population of people who suffer from trigger finger (TF) in terms of demographic (Gender, age, occupation, etc.); motor skills (hand function); the Consequences of the disease on a person's daily functioning and impact on quality of life.

The study will also attempt to examine the suitability of several common assessment tool for evaluation of hand rehabilitation Patients who suffer from TF.

Information obtained from the study will enable a deeper comprehension of the consequences of TF on the patient and will be the first step in developing a protocol assessment and evidence-based treatment in this population.


Eligibility criteria: Inclusion Criteria:

* Age 20 and above.
* Men and Women.
* diagnosed with Trigger Finger.

Exclusion Criteria:

* Trauma in upper Extremity.
* Cognitive difficulties that are blocking the ability to answer the questionnaires (dementia, head injury).
* Pregnant women.
* participants who didnt completed all Assessments.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Sherutey Briut Clalit
Study officials:
affiliation: Sherutey Briut Clalit
name: Michaeil Michaeilovich, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03752502: Effects of Cerebral and Peripheral Electrical Stimulation on Conditioned Pain Modulation in Healthy Subjects.
Official title: Effects of Cerebral and Peripheral Electrical Stimulation on Conditioned Pain Modulation in Healthy Subjects.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Healthy Volunteers
Lead sponsor: Universidade Federal do Piauí
Sponsor class: OTHER
First posted: 2018-11-26
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The Neuromatrix pain model and new findings on pain chronification process point to a greater efficacy of treatments that address central and peripheral rather than only peripheral structures. Both cerebral and peripheral electrical stimulations can modulate brain areas involved in pain processing. However, their effects on pain modulation systems and clinical outcomes are lacking.

This study aims to investigate the efficacy of transcranial direct current stimulation (tDCS) and peripheral electrical stimulation (PES) alone as well tDCS combined with PES on pressure pain threshold and conditioned pain modulation in healthy subjects.


Eligibility criteria: Inclusion Criteria:

Healthy subjects without medical complaints.

Exclusion Criteria:

Concurrent medication likely to affect cognitive performance pregnancy or possible pregnancy history of drug or alcohol abuse or dependence recent head injury (in the last 3 months) history of seizure or stroke.

Primary outcomes:
measure: Pressure pain threshold
timeFrame: Pre and Post-test (immediately after tDCS)
measure: Conditioned pain modulation
timeFrame: Pre and Post-test (immediately after tDCS)
Secondary outcomes:
Other outcomes:
measure: Anxiety
timeFrame: Pre-test (before tDCS)
measure: Depression
timeFrame: Pre-test (before tDCS)
measure: Pain catastrophizing
timeFrame: Pre-test (before tDCS)
Locations:
city: Parnaíba
country: Brazil
facility: Department of Physical Therapy. Federal University of Piaui
state: Piauí
Study officials:
affiliation: Federal University of Piaui
name: Fuad Hazime, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02059902: Continuous Lidocaine Infusion for Management of Perioperative Burn Pain
Official title: Continuous Lidocaine Infusion for Management of Perioperative Burn Pain
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Thermal Burns
Keywords: Pain management
Narcotic consumption
Skin graft
Lead sponsor: HealthPartners Institute
Sponsor class: OTHER
First posted: 2014-02-11
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Thermal injury results in one of the most intense and prolonged forms of pain the body can experience. Opioid narcotics are the most powerful drugs for acute and chronic pain, and their use in the perioperative period has been the mainstay of treatment; although medication requirements in burn patients are often underestimated. More medication may not be the answer, as relatively large doses of short acting opioids in the operative theater are associated with greater postoperative opioid consumption and higher pain scores. Furthermore, extensive use of opioids has resulted in the development of by hyperalgesia and allodynia. Lidocaine is an amide local anesthetic that has analgesic, anti-hyperalgesic, antiarrhythmic, and anti-inflammatory properties. Over the past 25 years, systemic lidocaine has been used for perioperative pain management in a variety of surgical procedures. The design of this study will examine if lidocaine will reduce the pain scores and narcotic utilization in patients undergoing surgical procedures for burn injuries. The intervention group will receive a bolus dose of lidocaine followed by a continuous infusion over 24 hours. The control group will get an equal volume of saline. The investigators will compare pain scores, opioid use, and narcotic equivalents based on body weight and burn surface area (BSA) grafted.


Eligibility criteria: Inclusion Criteria:

* Burn patient ≥ 18 years of age
* Burn patient scheduled to go to OR for excision and/or grafting procedure

Exclusion Criteria:

* Burn patient \< 18 years of age
* Intubated patient on sedation drip
* Prolonged hypotension defined as Systolic Blood Pressure (SBP) \< 90 mm/Hg for greater than 30 minutes in the pre-op area
* Severe underlying cardiovascular disease (documented ejection fraction \< 40%)
* Documented conduction block, bradycardia or active congestive heart failure
* Documented active gastritis or ulcers
* Previous steroid medication history if documented adrenal insufficiency
* Patient with documented liver disease
* Patient with epilepsy or known seizure disorder
* Pregnant Women

Primary outcomes:
measure: Narcotic Consumption (Measured in mg/kg Narcotic Consumption)
timeFrame: 24-hours post surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Saint Paul
country: United States
facility: Regions Hospital
state: Minnesota
Study officials:
affiliation: Regions Hospital
name: William Mohr, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Regions Hospital
name: Sandi Wewerka, MPH
role: STUDY_DIRECTOR
References:
Clinical trial NCT04133402: Fertility After Intrauterine Tamponing Balloon: Where Are we
Official title: Evaluation of Fertility of Patients With a History of Postpartum Hemorrhage, Complicating Low-dose Delivery With Intrauterine Tamponade Treatment
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hemorrhage Postpartum
Fertility Disorders
Keywords: Hemorrhage Post-partum
Fertility
Uterine balloon tamponade
Vaginal Birth
Lead sponsor: University Hospital, Lille
Sponsor class: OTHER
First posted: 2019-10-21
Enrollment: 59
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Major patients with postpartum haemorrhage after vaginal delivery between 2012 and 2017 in Valenciennes maternity and the CHRU Lille, treated by intrauterine tamponade therapy.

Brief summary: Today, few data are available on the patient's fertility following intrauterine tamponade balloon (BTIU) used for postpartum hemorrhage (PPH) after vaginal delivery (AVB). Several studies have concluded that there are no fertility disorders after conservative surgical treatment or embolization. BTIU is an essential treatment in the management of PPH. The aim was to evaluate post-BTIU fertility and the appearance of gynecological symptoms.

This is a bicentric retrospective study (Valenciennes, Lille, France), between 2012 and 2017. The data will be collected by telephone interview on fertility and various gynecological functional symptoms.


Eligibility criteria: Inclusion Criteria:

* Vaginal birth
* Post partum haemorrhage
* Intrauterine tamponing balloon
* Between 2012 and 2017
* CHRU Lille and CH Valenciennes

Exclusion Criteria:

* Minor patients
* Initial intake started in another center (postpartum transfer).
* Refusal to participate in the study
* Invasive treatments for postpartum haemorrhage
* Caesarean

Primary outcomes:
measure: Frequency of infertility
timeFrame: 7 years
Secondary outcomes:
measure: Time to obtain a new pregnancy evaluating the stop of contraceptionand desire for pregnancy
timeFrame: 7 years
measure: Frequency of gynecological complications after use of an intrauterine tamponade balloon.
timeFrame: 7 years
measure: Type of gynecological complications after use of an intrauterine tamponade balloon.
timeFrame: 7 years
measure: the frequency of obstetric complications for the next pregnancy
timeFrame: 7 years
measure: type of obstetrical complications
timeFrame: 7 years
measure: Frequency of recurrent postpartum haemorrhage in the next pregnancy
timeFrame: 7 years
Other outcomes:
Locations:
city: Lille
country: France
facility: Hôpital Roger Salengro, CHU
Study officials:
affiliation: University Hospital, Lille
name: Charles Garabedian, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01528202: Tart Cherries and Melatonin Content
Official title: Effect of Tart Cherry Juice (Prunus Cerasus) on Melatonin Levels and Sleep Quality
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sleep
Keywords: Sleep, circadian cycle, melatonin
Lead sponsor: Northumbria University
Sponsor class: OTHER
Collaborators: name: University of Surrey
First posted: 2012-02-07
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 39
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The aim of this investigation was to examine the effects of tart Montmorency cherry juice on urinary 6-sulfatoxymelatonin and sleep quality using a double-blind, placebo-controlled, cross-over design.

Detailed description: The aim of the study is to examine the efficacy of tart cherry juice on sleep quality, quantity, and timing. Naturally circulating melatonin is instrumental in regulating sleep/wake schedules. Tart Montmorency cherries (Prunus Cerasus) contain high levels of melatonin and may be a useful intervention to supplement for realignment of circadian phase and by increasing the robustness of circadian amplitude. In normal healthy adults, with experimentally induced phase advanced circadian misalignment, the administration of a 3mg supplement of melatonin significantly increased sleep architecture characteristics. In this study we want to examine the efficacy of tart cherry juice in increasing urinary levels of melatonin and the subsequent impact this will have on sleep parameters.

Eligibility criteria: Inclusion Criteria:

* Equal numbers of healthy, non-pathological males and females aged between 18-39.

Exclusion Criteria:

* history of epilepsy, current episode of major depressive disorder or anxiety disorder, or a current sleep problem or an inability to comprehend English, travel over two time zones within the last six months, excessive alcohol (over 3 units per day) or caffeine consumption (more than 6 caffeinated drinks or 1 after 6pm), a smoker, a shift worker, a familial history of diabetes, users of medication or supplements, or if the participant is pregnant or currently lactating.

Primary outcomes:
measure: urinary 6-sulphatoxymelatonin
timeFrame: continually for 48 hours
Secondary outcomes:
measure: Sleep quality
timeFrame: continually throughout the duration of the study
Other outcomes:
Locations:
city: Newcastle upon Tyne
country: United Kingdom
facility: Northumbria University
state: Tyne and Wear
Study officials:
affiliation: Northumbria University
name: Glyn Howatson, PhD
role: PRINCIPAL_INVESTIGATOR
References: